This article was originally published in The Gray Sheet
Enter agreement under which Abbott will manufacture privately held Sonus Pharmaceuticals' first product line, the EchoGen echocardiology and general radiology ultrasound contrast agents, according to a July 13 press release. Terms of the deal were not disclosed. Sonus plans to market the agents itself in the U.S. and is in discussions with more than one firm for international distribution. Sonus plans to begin EchoGen clinical trials by the end of the year....
You may also be interested in...
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake – but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.